SNDX - Kura Oncology down 15% on KO-539 safety signals in early-stage study

Kura Oncology (KURA) slumps 15% premarket on light volume in apparent reaction to the release on an abstract on leukemia candidate KO-539 that will be presented at the American Society of Hematology ((ASH)) Annual Meeting in early December.Preliminary results from the first three participants in a 30-subject Phase 1 study in patients with relapsed/refractory acute myeloid leukemia ((AML)) showed safety signals, including severe (Grade 3) tumor lysis syndrome (a deadly complication of blood cancers) at 50 mg and a severe embolic (blood clotting) event at 100 mg. There were no deaths but two of the patients discontinued treatment due to cancer progression, The third, with certain co-mutations, achieved complete remission after two cycles of 100 mg.KO-539 is an oral selective inhibitor of the menin-MLL protein-protein interaction, a key pathway in MLL-rearranged leukemias (AML and ALL). The company says it produces an anti-leukemic effect by inducing myeloid differentiation in immature cells called AML

For further details see:

Kura Oncology down 15% on KO-539 safety signals in early-stage study